{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:20:07Z","timestamp":1789654807687,"version":"4.0.1"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Abbreviations: DILI: drug-induced liver injury, HBV: Hepatitis B virus, LFT: liver function test, RRMS: Relapsing\u2013remitting multiple sclerosis, UDCA: ursodeoxycholic acid. Rituximab is a human chimeric monoclonal antibody that targets CD20 on B cells. The incidence of rituximab-associated drug-induced liver injury (DILI) is 19 cases per 100\u2009000 people annually. This condition is characterized by a rapid increase in aminotransferase levels and hepatocellular injury, primarily due to reactivation of the hepatitis B virus (HBV). Nevertheless, there have been rare cases of DILI occurring in the absence of HBV reactivation. This case presents a 25-year-old male with relapsing\u2013remitting multiple sclerosis (RRMS) that was treated with rituximab. After treatment, the patient demonstrated a hepatocellular damage pattern and biopsy confirmed the diagnosis. Following the administration of ursodeoxycholic acid (UDCA), the patient\u2019s liver function tests (LFTs) returned to normal levels, demonstrating that DILI from rituximab can occur after any infusion, regardless of therapy duration or dosage.<\/jats:p>","DOI":"10.1093\/omcr\/omaf003","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T14:47:38Z","timestamp":1752504458000},"source":"Crossref","is-referenced-by-count":3,"title":["Drug-induced liver injury secondary to rituximab use"],"prefix":"10.1093","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7933-0507","authenticated-orcid":false,"given":"Samantha Melanie","family":"Armendariz-Pineda","sequence":"first","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico , 411A Escolar Street, Copilco Universidad, Coyoacan, 04360 Mexico City,","place":["Mexico"]},{"name":"Department of Hepatology, Internal Medicine Service, Hospital General Dr. Manuel Gea Gonzalez , 4800 Calzada de Tlalpan, Belisario Dom\u00ednguez Section 16, Tlalpan , 14080 Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1133-2944","authenticated-orcid":false,"given":"Andres Manuel","family":"Vargas-Beltran","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Internal Medicine Service, Hospital General Dr. Manuel Gea Gonzalez , 4800 Calzada de Tlalpan, Belisario Dom\u00ednguez Section 16, Tlalpan , 14080 Mexico City,","place":["Mexico"]},{"name":"Faculty of Medicine, Meritorious Autonomous University of Puebla , 2702 13 Sur Street, Los Volcanes, 72420 Heroica Puebla de Zaragoza,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Juliana","family":"Corredor-Nassar","sequence":"additional","affiliation":[{"name":"Internal Medicine Service , , 4800 Calzada de Tlalpan, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]},{"name":"Hospital General Dr. Manuel Gea Gonzalez , , 4800 Calzada de Tlalpan, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Gamboa-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Department of Pathology , , 15 Vasco de Quiroga, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]},{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n , , 15 Vasco de Quiroga, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Arturo","family":"Santos-Reyes","sequence":"additional","affiliation":[{"name":"Department of Pathology , , 15 Vasco de Quiroga, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]},{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n , , 15 Vasco de Quiroga, Belisario Dominguez Section 16, Tlalpan, 14080 Mexico City ,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cordova-Gallardo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, National Autonomous University of Mexico , 411A Escolar Street, Copilco Universidad, Coyoacan, 04360 Mexico City,","place":["Mexico"]},{"name":"Department of Hepatology, Internal Medicine Service, Hospital General Dr. Manuel Gea Gonzalez , 4800 Calzada de Tlalpan, Belisario Dom\u00ednguez Section 16, Tlalpan , 14080 Mexico City,","place":["Mexico"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"2025072710514221700_ref1","doi-asserted-by":"publisher","first-page":"e78856","DOI":"10.1371\/journal.pone.0078856","article-title":"Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to fab 2 fragments","volume":"8","author":"Latus","year":"2013","journal-title":"PLoS One"},{"key":"2025072710514221700_ref2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3138\/canlivj-2020-0009","article-title":"Rituximab-induced autoimmune hepatitis: a case study and review of the literature","volume":"3","author":"Galiatsatos","year":"2020","journal-title":"Can Liver J"},{"key":"2025072710514221700_ref3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.5505\/tjh.2012.98853","article-title":"Rituximab-related reversible hepatocellular damage","volume":"29","author":"Toprak","year":"2012","journal-title":"Turk J Hematol"},{"key":"2025072710514221700_ref4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"2025072710514221700_ref5","doi-asserted-by":"publisher","first-page":"s104","DOI":"10.7861\/clinmedicine.16-6-s104","article-title":"Drug-induced liver injury","volume":"16","author":"Katarey","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"2025072710514221700_ref6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/hep.32327","article-title":"A revised electronic version of RUCAM for the diagnosis of DILI","volume":"76","author":"Hayashi","year":"2022","journal-title":"Hepatology"},{"key":"2025072710514221700_ref7","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1089\/cbr.2010.0806","article-title":"A case of rituximab-induced hepatitis","volume":"25","author":"Del Prete","year":"2010","journal-title":"Cancer Biother Radiopharm"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/7\/omaf003\/63748852\/omaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/7\/omaf003\/63748852\/omaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T14:51:49Z","timestamp":1753627909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaf003\/8200181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":7,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaf003","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,7]]},"article-number":"omaf003"}}